MELBOURNE, August 22, 2026, 09:07 AEST
- CSL closed Friday at A$168.30, up 25.0% from Monday’s pre-results close.
- The rally added an estimated A$16.1 billion to the company’s market value.
- FY27 guidance points to about 5% underlying profit growth despite flat revenue.
CSL Limited ASX:CSL added an estimated A$16.1 billion in market value during results week. The shares ended Friday at A$168.30, up 25.0% from Monday’s A$134.60 close. They slipped 1.69% in the final session as the Australian market closed for the weekend.
That gain matters because CSL also reported its first annual statutory loss since listing. Investors instead priced the reset beyond the impairment charge. Management forecast roughly 5% underlying profit growth in FY27, even as revenue stays near FY26 levels.
| Results-week marker | Share price | Move |
|---|---|---|
| Monday pre-results close | A$134.60 | Baseline |
| Tuesday close | A$157.82 | +17.25% |
| Thursday reference close | A$171.20 | +27.19% vs Monday |
| Friday close | A$168.30 | +25.04% vs Monday |
The market’s verdict was sharp. CSL drove much of the healthcare sector’s 9.5% weekly rise while the S&P/ASX 200 lost about 0.7%. Friday volume reached 2.69 million shares.
FY26 revenue was US$15.80 billion. Underlying NPATA attributable to shareholders reached US$3.10 billion. Both were little changed in reported currency, but statutory NPAT swung to a US$2.58 billion loss after large non-cash charges.
| FY26 measure | FY26 | Year-on-year |
|---|---|---|
| Revenue | US$15.80bn | -1% at constant currency |
| Underlying NPATA | US$3.10bn | -2% at constant currency |
| Reported NPAT | -US$2.58bn | From +US$3.00bn |
| Operating cash flow | US$3.51bn | -1% |
| Underlying NPATA EPS | US$6.43 | -3% |
The loss reflected US$7.1 billion of pre-tax impairment and related charges. CSL Vifor accounted for US$4.1 billion, or about 58% of that total. The charges equalled almost 45% of annual revenue, but did not consume cash.
Interim Chief Executive Gordon Naylor said, “CSL is positioned for a return to sustainable growth.” The company is simplifying operations and shifting investment toward commercial execution and selected development programs. CSL FY26 results
| Business or driver | FY26 result | FY27 signal |
|---|---|---|
| CSL Behring | US$11.39bn revenue, -1% | Mid-single-digit growth |
| Immunoglobulin | US$6.25bn revenue | Mid-to-high single-digit growth |
| CSL Vifor | US$2.38bn revenue, +3% | About 25% decline |
| CSL Seqirus | US$2.03bn revenue, -8% | Low-single-digit growth |
| Cost savings | US$176m delivered | US$400m target |
The next phase depends on Behring. Immunoglobulin demand remains firm, while collection efficiency should support margins. The drag is Vifor, where generics and reimbursement changes are expected to cut FY27 revenue by about one quarter.
Cost delivery offers the clearest bridge. FY26 savings of US$176 million exceeded plan. CSL targets US$400 million in FY27 and as much as US$550 million in FY28, against US$799 million of pre-tax restructuring costs booked in FY26.
| Analyst recommendation | Target | Action and date |
|---|---|---|
| UBS — Buy | A$181 | Raised from A$158, Aug. 20 |
| CLSA — Outperform | A$180 | Raised from A$130, Aug. 20 |
| Macquarie — Hold | A$108 | Maintained, Aug. 18 |
Broker views remain unusually wide. UBS and CLSA lifted targets after the result, while Macquarie stayed cautious. Investing.com’s current aggregate target is A$163.62, 2.8% below Friday’s close, despite an overall Buy reading.
The A$1.1 billion FY27 buyback adds support. It equals about 1.3% of CSL’s A$82.0 billion market value at Friday’s close. That is useful, but smaller than this week’s A$16.1 billion re-rating.
For the week ahead, investors will test whether the rally can hold above the new broker targets. Attention will centre on Behring margins, Vifor erosion and progress toward the US$400 million savings goal. The ASX reopens Monday.
Risks: Vifor’s decline could exceed guidance, plasma pricing may weaken, or savings may arrive later than planned. Currency moves remain another headwind; CSL estimates about US$50 million at current rates.
Related articles: ASX:CSL
